Obesity effects on nitrazepam disposition.

Nitrazepam pharmacokinetics were studied in 14 obese (mean +/- s.e. mean body weight 107 +/- 9 kg; percent ideal body weight [IBW] 166 +/- 12%) and 14 normal body weight (63 +/- 3 kg; percent IBW 98 +/- 2%) subjects. After an overnight fast, each subject ingested 10 mg nitrazepam orally. Nitrazepam concentrations were determined in plasma samples obtained over the following 72 h. Comparison of peak nitrazepam plasma concentration (94.2 +/- 10.3-obese vs 119 +/- 14.6 ng ml-1; NS) and time required after drug administration to reach peak concentration (1.52 +/- 0.24-obese vs 1.59 +/- 0.36 h; NS) indicated no differences between obese and control subjects. Elimination half-life was markedly increased in obese subjects (33.5 +/- 2.2 vs 23.9 +/- 1.2 h; P less than 0.001) due to increased apparent volume of distribution (Vd) (290 +/- 45 vs 137 +/- 12 l; P less than 0.005). Oral clearance was also increased in the obese subjects (101 +/- 12.4 vs 66.8 +/- 12.4 ml min-1; P less than 0.02). Extent of nitrazepam binding to plasma proteins was slightly decreased in obese subjects (% unbound--19.7 +/- 0.4-obese vs 17.9 +/- 0.3%; P less than 0.005). Correction of both Vd (2.62 +/- 0.17-obese vs 2.22 +/- 0.19 l kg-1; NS) and clearance (0.93 +/- 0.06-obese +/- 1.07 +/- 0.07 ml min-1 kg-1; NS) for total body weight (TBW) suggested that increases in obese subjects of both of these parameters were a function of body weight.(ABSTRACT TRUNCATED AT 250 WORDS)

[1]  D R Abernethy,et al.  Age, sex, and nitrazepam kinetics: Relation to antipyrine disposition , 1985, Clinical pharmacology and therapeutics.

[2]  D. Greenblatt,et al.  Kinetics of diazepam, midazolam, and lorazepam in cigarette smokers. , 1985, Chest.

[3]  D. Greenblatt,et al.  Simplified gas chromatographic assay of underivatized nitrazepam in plasma. , 1985, Journal of chromatography.

[4]  D. Greenblatt,et al.  The Influence of Obesity on the Pharmacokinetics of Oral Alprazolam and Triazolam , 1984, Clinical pharmacokinetics.

[5]  D. Greenblatt,et al.  In vitro correlates of benzodiazepine cerebrospinal fluid uptake, pharmacodynamic action and peripheral distribution. , 1983, The Journal of pharmacology and experimental therapeutics.

[6]  D. Greenblatt,et al.  Current Status of Benzodiazepines , 1983 .

[7]  D. Greenblatt,et al.  Enhanced glucuronide conjugation of drugs in obesity: studies of lorazepam, oxazepam, and acetaminophen. , 1983, The Journal of laboratory and clinical medicine.

[8]  D. Greenblatt,et al.  Concentration‐independent plasma protein binding of benzodiazepines , 1983, The Journal of pharmacy and pharmacology.

[9]  A. Janssens,et al.  Effect of age and liver cirrhosis on the pharmacokinetics of nitrazepam. , 1983, British journal of clinical pharmacology.

[10]  D. Greenblatt,et al.  Drug therapy. Current status of benzodiazepines. , 1983, The New England journal of medicine.

[11]  A. Melander,et al.  Influence of food and of age on nitrazepam kinetics. , 1982, Drug-nutrient interactions.

[12]  L. Kangas,et al.  Clinical Pharmacokinetics of Nitrazepam , 1981, Clinical pharmacokinetics.

[13]  S. Schenker,et al.  Cimetidine impairs elimination of chlordiazepoxide (Librium) in man. , 1980, Annals of internal medicine.

[14]  L. Kangas.  Urinary elimination of nitrazepam and its main metabolites. , 2009, Acta pharmacologica et toxicologica.

[15]  John G. Wagner,et al.  Fundamentals of Clinical Pharmacokinetics , 1975 .